Nano-technology uses virus' coats to fool cancer cells

While there have been major advances in the detection, diagnosis, and treatment of tumors within the brain, brain cancer continues to have a very low survival rate in part to high levels of resistance to treatment. New research published in BioMed Central's open access journal Journal of Nanobiotechnology has used Sendai virus to transport Quantum Dots (Qdots) into brain cancer cells and to specifically bind Qdots to epidermal growth factor receptor (EGFR) which is often over-expressed and up-regulated in tumors. By molecular-labeling cancer cells this nanoparticle technology could be used to aid diagnosis.

Qdots are tiny fluorescent particles, smaller than a virus, and over 1000 times smaller than a cell, which can be linked to biological molecules, such as antibodies. Once linked, the fluorescence would make it easy to find which cells contain the protein the antibody recognizes, and where in the cell this protein is located. However there have been problems getting the Qdots into cells without them clumping, or being packaged in to endosomes, and excreted from the cells as waste.

Researchers from the City College of New York have overcome this problem by coating the Qdots in lipid and protein coats based on Sendai virus. Prof Maribel Vazquez explained, "While cells have complex defense mechanisms to protect themselves against attack, viruses have evolved ways to fool the cell into letting them in. We were able to exploit these mechanisms by fusing inactivated mouse parainfluenza virus with liposomes containing Qdots. The Qdots were in turn attached to an antibody against EGFR. So, once inside the cell, the Qdot-antibody complexes were able to bind to the receptor and the amount of bound complex could be monitored by measuring Qdot fluorescence."

This study looked at the level of EGFR as a marker for cancer but the Qdots could be attached to any antibody. Antibody-Qdot sets would allow rapid identification of different cancer types, determine potential chemotherapy resistance, and lead a more individualized treatment plan.

Media Contact
Dr Hilary Glover
Scientific Press Officer, BioMed Central
Tel: 44-20-3192-2370
Mob: 44-778-698-1967
Email: hilary.glover@biomedcentral.com

1. Sendai Virus-based Liposomes Enable Targeted Cytosolic Delivery of Nanoparticles in Brain Tumor-Derived Cells Veronica Dudu, Veronica Rotari and Maribel Vazquez. Journal of Nanobiotechnology (in press)

Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy.

Article citation and URL available on request at press@biomedcentral.com on the day of publication.

2. Journal of Nanobiotechnology is an open access, peer-reviewed, online journal communicating scientific and technological advances in the fields of medicine and biology, with an emphasis in their interface with nanoscale sciences. The journal provides biomedical scientists and the international biotechnology business community with the latest developments in the growing field of Nanobiotechnology.

3. BioMed Central (http://www.biomedcentral.com/) is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector.